Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy

Background/Aims: Point mutations in the 23S ribosomal RNA gene have been associated with Helicobacter pylori (H. pylori) clarithromycin resistance and bismuth-based quadruple therapy (BQT) is one of the options for the treatment of clarithromycin-resistant H. pylori. Current H. pylori treatment guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Sang-Gon, Lim, Chul-Hyun, Kang, Hee-Jun, Choi, Arum, Kim, Sukil, Oh, Jung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369116/
https://www.ncbi.nlm.nih.gov/pubmed/35956057
http://dx.doi.org/10.3390/jcm11154440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369116/
https://www.ncbi.nlm.nih.gov/pubmed/35956057
http://dx.doi.org/10.3390/jcm11154440

Ejemplares similares